Beyond Genotyping & Tissue: Leveraging a Liquid Biopsy, Methylation-Based Platform Across the Cancer Care Continuum
Time: 9:00 am
day: Day Two
Details:
- GRAIL’s methylation technology overview and clinical studies
- Overview of Tumor Methylation Fraction (TMeF) for molecular response, risk stratification, prognosis/prediction and MRD
- Application focus: The use of GRAIL’s methylation technology in early-stage NSCLC prognosis and hematological cancer
